News : 2013 : March

Hepatobiliary Course Brings Together the Most Innovative Research in Hepatology

Over 100 physicians and medical professionals from around the country gathered at the Ritz-Carlton Hotel in Coconut Grove, FL for the bi-annual Hepatobiliary Disease in Clinical Practice Update:XX presented by the University of Miami Miller School of Medicine’s Division of Hepatology and the Schiff Center for Liver Diseases. The two day course focused on the current state of hepatobiliary diseases and featured presentations by specialists at the forefront of the field. Course Director Dr. Eugene Schiff selected the faculty for the course based on their groundbreaking research so that only the most up-to-date information could be presented and discussed. The scope of the course was comprehensive, encompassing the most important research on antiviral therapy for liver transplant patients, management of hepatic encephalopathy, identification of alpha-1-antitrypsin deficiency, co-infection of HBV and HCV with HIV, promising therapies for NASH, the spectrum of porphyria, management of sclerosing cholangitis, and other relevant topics in hepatology. These topics were presented by professors from leading research institutions across the country who have dedicated years of study to researching their areas of interest.

To demonstrate the applications of the newest research, the course lecturers participated in a panel in which they analyzed real case studies on patients seen at the Schiff Center for Liver Diseases presented by Schiff Center and Division of Hepatology research coordinators, nurses, and research fellows. The course faculty gave their input on treatment, diagnosis and management of the case study patient and engaged in lively discussion moderated by Dr. Schiff.

In all, the Hepatobiliary Disease in Clinical Practice Update:XX was a tremendous effort by the University of Miami Miller School of Medicine that united medical professionals for the ultimate goal of providing the most up to date information about hepatobiliary diseases and providing the opportunity to connect with hepatology’s leaders from around the nation. With experiments on interferon free treatments for viral hepatitis on the rise, increased investigation into overlapping autoimmune diseases, and the phenomenal work being done in liver transplantation, there will undoubtedly be plenty of new research and studies in the coming two years that will be featured in the next Hepatobiliary Disease in Clinical Practice Update.